ЁЯФ┤ LIVE: рдкреНрд░рдзрд╛рдирдордВрддреНрд░реА рдореЛрджреА рдХрд╛ рд░реИрд▓реА рдореЗрдВ рд╕рдВрдмреЛрдзрди | ЁЯФ┤ рдмрдЬрдЯ 2024: рдЬрд╛рдиреЗрдВ рдХреНрдпрд╛ рд╣реИ рдЦрд╛рд╕ | ЁЯФ┤ IPL 2024: рдЯреАрдо рдЗрдВрдбрд┐рдпрд╛ рдХреА рдШреЛрд╖рдгрд╛
рдмреНрд░реЗрдХрд┐рдВрдЧ
тАв рдкреНрд░рдзрд╛рдирдордВрддреНрд░реА рдореЛрджреА рдЖрдЬ рдЙрддреНрддрд░ рдкреНрд░рджреЗрд╢ рдореЗрдВ рд░реИрд▓реА рдХреЛ рд╕рдВрдмреЛрдзрд┐рдд рдХрд░реЗрдВрдЧреЗ тАв рдмрдЬрдЯ 2024: рдордзреНрдпрдо рд╡рд░реНрдЧ рдХреЛ рдмрдбрд╝реА рд░рд╛рд╣рдд рдорд┐рд▓рдиреЗ рдХреА рдЙрдореНрдореАрдж тАв рдЖрдИрдкреАрдПрд▓ 2024: рдЯреАрдо рдЗрдВрдбрд┐рдпрд╛ рдХреА рдШреЛрд╖рдгрд╛ рдЖрдЬ тАв рд░рд╛рдо рдордВрджрд┐рд░: рдЕрдпреЛрдзреНрдпрд╛ рдореЗрдВ рднрд╡реНрдп рддреИрдпрд╛рд░рд┐рдпрд╛рдВ рдкреВрд░реА тАв рдмреАрдЬреЗрдкреА рдХрд╛ рдорд╣рд╛рдкреНрд░рдмрдВрдзрди: 2024 рдЪреБрдирд╛рд╡ рдХреА рддреИрдпрд╛рд░рд┐рдпрд╛рдВ рддреЗрдЬ

Angelica Peebles

Articles by Angelica Peebles

Eli Lilly, Regeneron among first companies selected for FDA initiative to speed review of new manufacturing facilities - CNBC

Business June 30, 2026

Eli Lilly and Regeneron are among the first seven companies the U.S. Food and Drug Administration selected for a pilot program designed to accelerate reviews of new domestic pharmaceutical manufacturя┐╜...

Novo Nordisk CEO says the drugmaker is more active than ever in seeking out deals - CNBC

Business May 7, 2026

Novo Nordisk is looking for deals more than ever before, the CEO of the Danish drugmaker said in an interview with CNBC on Wednesday. "If our ambition is to help hundreds of millions of patients ouя┐╜...

FDA commissioner defends agency's drug approval decisions after wave of backlash - CNBC

Business May 6, 2026

U.S. Food and Drug Administration Commissioner Marty Makary defended himself in a CNBC interview aired Tuesday after months of pressure over recent drug rejections.┬а The relentless heat reached a ne...

Intellia Therapeutics says its Crispr-based treatment succeeds in pivotal trial - CNBC

Business April 28, 2026

Intellia Therapeutics said its Crispr-based treatment for a rare swelling condition met its goals in a late-stage trial, marking a milestone for the field of gene editing and putting the company on tя┐╜...

Revolution Medicines' potential breakthrough pancreatic cancer drug succeeds in late-stage trial - CNBC

Business April 14, 2026

Revolution Medicines' drug for pancreatic cancer succeeded in a highly anticipated Phase 3 trial, almost doubling the typical length of survival and slashing the risk of death by 60% versus chemotherя┐╜...